Loading...
Market
Will Briumvi receive FDA approval for additional indications by end of 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements and press releases
Story
TG Therapeutics ($TGTX) Reports Positive ENHANCE Phase 3b Data on Briumvi for Multiple Sclerosis
Oct 14, 2024, 11:37 AM
TG Therapeutics ($TGTX) has released new data from its ENHANCE Phase 3b study, showing that rapid 30-minute infusions of Briumvi (ublituximab-xiiy) are well tolerated in patients with relapsing forms of multiple sclerosis. This comes amid comparisons with SubQ Ocrevus, which requires a 10-minute delivery of 23ml of fluid under the skin, potentially causing discomfort and bruising. The total treatment time for SubQ Ocrevus is approximately 1.5 hours, compared to 4.5 hours for IV Ocrevus. KOLS do not favor SubQ Ocrevus, and the Briumvi switching trial is showing promising results.
View original story
Similar markets
Only FDA • 25%
FDA and EMA • 25%
FDA, EMA, and MHRA • 25%
None • 25%
Yes • 50%
No • 50%
Lung cancer related indication • 25%
Other cancer indication • 25%
Non-cancer indication • 25%
No new approval • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
